Press Releases :: VolitionRx Ltd (VNRX)

Mar 31, 2021 • 8:30 AM EDT VolitionRx Limited Announces Publication of Significant Nu.Q® Capture Mass Spectrometry Paper

Mar 30, 2021 • 8:30 AM EDT VolitionRx Limited Appoints Dr. Tom Butera DVM as Chief Executive Officer for Volition Veterinary Subsidiary

Mar 29, 2021 • 4:10 PM EDT VolitionRx Limited Appoints Two New Directors

Mar 22, 2021 • 4:10 PM EDT VolitionRx Limited Announces Full Fiscal Year 2020 Financial Results and Business Update

Mar 17, 2021 • 8:00 AM EDT New Data Demonstrates Nu.Q® is Effective in Monitoring Treatment of Sepsis

Mar 16, 2021 • 8:30 AM EDT VolitionRx Limited Schedules Full Fiscal Year 2020 Earnings Conference Call and Business Update

Mar 8, 2021 • 4:15 PM EST VolitionRx Limited to Present at Conferences in March 2021

Feb 12, 2021 • 9:25 AM EST VolitionRx Limited Announces Closing of $20 Million Underwritten Public Offering of Common Stock

Feb 10, 2021 • 9:18 AM EST VolitionRx Limited Announces Pricing of $20 Million Underwritten Public Offering of Common Stock

Feb 9, 2021 • 4:01 PM EST VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock